{
  "story_id": "1189ad832d18be7318d42d556491acc4",
  "desk": "drm3",
  "revision": 1,
  "published_at": "2026-11-21T02:40:01.000Z",
  "content_hash": "7cdb776d1d9d6acf36f4cd212225cd85de1bac8faa870cd21357e4943532b491",
  "hash_basis": "sha256 over `headline\\ndek\\nprose`, plus `\\n` + the canonical citations JSON when any source is placed, plus `\\n#blog` for blogs",
  "basis": {
    "headline": "Phase I trial shows ERAS-0015 effective for RAS-mutant lung and pancreatic cancer",
    "dek": "ERAS-0015 pan-RAS drug demonstrated safety and tumor shrinkage in early clinical trial.",
    "prose": "AURORAS-1 Phase I trial results for ERAS-0015 were presented 18-20 November 2026 at the 38th EORTC-NCI-AACR Symposium in Barcelona, Spain. [^1]\n\nDr. Judy Wang stated ERAS-0015 achieved 44% tumor response rate in RAS-mutant pancreatic cancer patients at 32mg dose. [^2] 9.8% of trial patients reported severe grade 3 or higher treatment-related side effects; no maximum tolerated dose was identified. [^3] ERAS-0015 is a pan-RAS molecular glue designed to block activated RAS protein growth signals that drive cancer progression [^4]\n\nThe AURORAS-1 trial began in June 2025, enrolled 148 patients, and remains actively recruiting additional participants [^5]",
    "cited": "[{\"statement\":\"AURORAS-1 Phase I trial results for ERAS-0015 were presented 18-20 November 2026 at the 38th EORTC-NCI-AACR Symposium in Barcelona, Spain.\",\"source\":\"Medical Xpress\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-11-21T02:40:01.000Z\",\"publisher_count\":1,\"sources\":[\"Medical Xpress\"],\"url\":\"https://medicalxpress.com/news/2026-11-pan-ras-molecular-safe-effective.html\"},{\"statement\":\"Dr. Judy Wang stated ERAS-0015 achieved 44% tumor response rate in RAS-mutant pancreatic cancer patients at 32mg dose.\",\"source\":\"Medical Xpress\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-11-21T02:40:01.000Z\",\"publisher_count\":1,\"sources\":[\"Medical Xpress\"],\"url\":\"https://medicalxpress.com/news/2026-11-pan-ras-molecular-safe-effective.html\"},{\"statement\":\"9.8% of trial patients reported severe grade 3 or higher treatment-related side effects; no maximum tolerated dose was identified.\",\"source\":\"Medical Xpress\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-11-21T02:40:01.000Z\",\"publisher_count\":1,\"sources\":[\"Medical Xpress\"],\"url\":\"https://medicalxpress.com/news/2026-11-pan-ras-molecular-safe-effective.html\"},{\"statement\":\"ERAS-0015 is a pan-RAS molecular glue designed to block activated RAS protein growth signals that drive cancer progression\",\"source\":\"Salud\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-11-20T10:23:31.000Z\",\"publisher_count\":1,\"sources\":[\"Salud\"],\"url\":\"https://www.20minutos.es/salud/farmaco-eras-0015-demuestra-ensayo-seguro-reduce-tumores-pulmon-pancreas_7063552_0.html\"},{\"statement\":\"The AURORAS-1 trial began in June 2025, enrolled 148 patients, and remains actively recruiting additional participants\",\"source\":\"Salud\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-11-20T10:23:31.000Z\",\"publisher_count\":1,\"sources\":[\"Salud\"],\"url\":\"https://www.20minutos.es/salud/farmaco-eras-0015-demuestra-ensayo-seguro-reduce-tumores-pulmon-pancreas_7063552_0.html\"}]",
    "kind": "news"
  },
  "receipt_verify": "Ed25519 over the dot-joined string `slice_hash.cursor_from.cursor_to.view.view_version.row_count`; public_key and sig are base64url of the raw 32-byte key / 64-byte signature",
  "receipt": {
    "slice_hash": "7541358865d9ba43e5c41cec99d1025ab177b0d9c0868acca8e7aae03401f8db",
    "cursor_from": "ingest:raw_newsroomfloor.stories:7541358865d9ba43",
    "cursor_to": "ingest:raw_newsroomfloor.stories:7541358865d9ba43",
    "view": "ingest:raw_newsroomfloor.stories",
    "view_version": "1",
    "row_count": 1,
    "hash_basis": "sha256 over the JSON array of {insertId, json} rows as received (normalized wire shape), computed before the BigQuery forward",
    "credits": 0.01,
    "price_per_100_rows_written": 1,
    "sig": "MQxMhdHXBCDCPhUj5RaT198q1ALWA0TPor_1LkgyHnbR-3KpW0aQqlFh0bz_X3-F0taP7n5RGUkWMXjIJEiCBg",
    "public_key": "bMUigy8O0jOnBxQ4Sc-5lwhIZ8LQVAhxMbR7qESVuUE",
    "signer_path": "lakehouse/data-extract/v1",
    "alg": "Ed25519",
    "signed": true
  },
  "receipt_note": "the ingest door's signed receipt for this revision, verbatim as the door returned it",
  "generation_chain": {
    "wire": {
      "stream": "fountain_news",
      "story_id": "70a4e651dddf9fc53a1bcf350f17a43f",
      "thread_id": "f90182e3f3a7fb031d5479a7665fe219",
      "thread_label": "AURORAS-1",
      "novelty": "UPDATE",
      "content_hash": "c005522f2ee930a5ee01a6c9f77bd2d65244ce93fee610a28a12adfd107df870",
      "compose": 3,
      "last_published_at": "2026-11-21T02:40:01.000Z",
      "read_receipt": {
        "slice_hash": "91fa07d99eb56c3d83b17d14446e3ff5c8b3960527aab58d24b709a0d02fe26f",
        "cursor_from": "eyJ0cyI6IjIwMjYtMTEtMjFUMDA6NDU6NTYuMDAwWiIsImlkIjoiYWQwMjQ3MmIyNWI1YzUzZWVjNDkwYTI3MTFhOTk2MzIiLCJ2IjoiMSJ9",
        "cursor_to": "eyJ0cyI6IjIwMjYtMTEtMjFUMDU6Mjk6MDYuMDAwMDAwWiIsImlkIjoiMjcxMGE0ZjYzYjMxMjdjZTY3ZGFkY2FkNzJmMmQxMzQiLCJ2IjoiMSJ9",
        "view": "v_fountain_news",
        "view_version": "1",
        "row_count": 42,
        "window_days": 3,
        "bytes_scanned": 2477455,
        "credits": 3.36,
        "price_per_100_rows": 8,
        "sig": "-Qzpy_Ou3XScxJ00EFhAelKZvVDjtJJ33TSDdqxHy4RYsy4ql5uPbbCjPqfDEtPKrB5xGcXgXEu4PgSw_mOoDg",
        "public_key": "bMUigy8O0jOnBxQ4Sc-5lwhIZ8LQVAhxMbR7qESVuUE",
        "signer_path": "lakehouse/data-extract/v1",
        "alg": "Ed25519",
        "signed": true
      },
      "landing": "air"
    },
    "written_at": "2026-11-21T06:32:59.211Z"
  },
  "cited_facts": [
    {
      "n": 1,
      "statement": "AURORAS-1 Phase I trial results for ERAS-0015 were presented 18-20 November 2026 at the 38th EORTC-NCI-AACR Symposium in Barcelona, Spain.",
      "source": "Medical Xpress",
      "instrument": "News",
      "claim_key": null,
      "url": "https://medicalxpress.com/news/2026-11-pan-ras-molecular-safe-effective.html",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 2,
      "statement": "Dr. Judy Wang stated ERAS-0015 achieved 44% tumor response rate in RAS-mutant pancreatic cancer patients at 32mg dose.",
      "source": "Medical Xpress",
      "instrument": "News",
      "claim_key": null,
      "url": "https://medicalxpress.com/news/2026-11-pan-ras-molecular-safe-effective.html",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 3,
      "statement": "9.8% of trial patients reported severe grade 3 or higher treatment-related side effects; no maximum tolerated dose was identified.",
      "source": "Medical Xpress",
      "instrument": "News",
      "claim_key": null,
      "url": "https://medicalxpress.com/news/2026-11-pan-ras-molecular-safe-effective.html",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 4,
      "statement": "ERAS-0015 is a pan-RAS molecular glue designed to block activated RAS protein growth signals that drive cancer progression",
      "source": "Salud",
      "instrument": "News",
      "claim_key": null,
      "url": "https://www.20minutos.es/salud/farmaco-eras-0015-demuestra-ensayo-seguro-reduce-tumores-pulmon-pancreas_7063552_0.html",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 5,
      "statement": "The AURORAS-1 trial began in June 2025, enrolled 148 patients, and remains actively recruiting additional participants",
      "source": "Salud",
      "instrument": "News",
      "claim_key": null,
      "url": "https://www.20minutos.es/salud/farmaco-eras-0015-demuestra-ensayo-seguro-reduce-tumores-pulmon-pancreas_7063552_0.html",
      "occurred_at": null,
      "published_at": null
    }
  ],
  "note": "A signature proves who filed this and that it has not changed since. It never makes a claim true. The dates on cited_facts (occurred_at, published_at) are the forge's, joined at read time; they are not part of the signed basis above."
}